Study guide

Decompensation, viral hepatitis and surveillance

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Decompensation, viral hepatitis and surveillance

Key Takeaways Explain This Topic AI

Ascitic neutrophils of at least 250 cells/microlitre support spontaneous bacterial peritonitis.

Albumin after large-volume paracentesis is calculated from the total volume removed.

Cirrhotic patients need ongoing HCC surveillance after successful hepatitis C treatment.

Last updated: October 2026

  • Complications of Decompensated Cirrhosis
  • 1. Ascites & Serum-Ascites Albumin Gradient (SAAG)

Ascites is the pathological accumulation of fluid within the peritoneal cavity. Diagnostic paracentesis is mandatory for every patient with newly detected ascites or any cirrhotic inpatient undergoing clinical deterioration.

The SAAG Calculation SAAG = Serum Albumin Concentration − Ascitic Fluid Albumin Concentration \text{SAAG} = \text{Serum Albumin Concentration} - \text{Ascitic Fluid Albumin Concentration} SAAG = Serum Albumin Concentration − Ascitic Fluid Albumin Concentration

Both samples should be drawn simultaneously.

High SAAG : SAAG Value: ≥ 11 g/L \ge 11\text{ g/L} ≥ 11 g/L ; Pathophysiological Mechanism: Portal Hypertension ; increased hydrostatic pressure in hepatic sinusoidal and splanchnic capillaries.; Common Causes: Cirrhosis ( > 80 % > 80\% > 80% ); congestive cardiac failure (Ascitic protein ≥ 25 g/L \ge 25\text{ g/L} ≥ 25 g/L ); Budd-Chiari syndrome (hepatic vein thrombosis); constrictive pericarditis

Low SAAG : SAAG Value: < 11 g/L < 11\text{ g/L} < 11 g/L ; Pathophysiological Mechanism: Normal Portal Pressure ; increased peritoneal capillary permeability or decreased plasma oncotic pressure.; Common Causes: Peritoneal carcinomatosis; peritoneal tuberculosis; nephrotic syndrome; acute pancreatitis; biliary ascites

Medical Management of Cirrhotic Ascites

Dietary Sodium Restriction: Limit daily sodium intake to 2000 mg/day 2000\text{ mg/day} 2000 mg/day ( 88 mmol/day 88\text{ mmol/day} 88 mmol/day ) . Fluid restriction is NOT indicated unless profound hypervolaemic hyponatraemia develops (serum sodium < 120 − 125 mmol/L < 120-125\text{ mmol/L} < 120 − 125 mmol/L ).

Diuretic Therapy: Dual therapy targeting secondary hyperaldosteronism and distal nephron sodium reabsorption:

Spironolactone: Aldosterone antagonist; starting dose 100 mg 100\text{ mg} 100 mg once daily, titrated every 3-5 days up to a maximum of 400 mg 400\text{ mg} 400 mg daily.

Frusemide: Loop diuretic; starting dose 40 mg 40\text{ mg} 40 mg once daily, titrated up to 160 mg 160\text{ mg} 160 mg daily.

Maintain the 100 mg : 40 mg ratio to preserve serum potassium balance. Target weight loss: 0.5 kg/day 0.5\text{ kg/day} 0.5 kg/day without peripheral oedema, or 1.0 kg/day 1.0\text{ kg/day} 1.0 kg/day with peripheral oedema.

Large-volume paracentesis: When more than 5 L is removed, albumin replacement is usually calculated against the total volume removed, often 8 g/L under local guidance. For 6 L, 8 × 6 = 48 g, not 8 g for only the litre above 5. Assess renal risk and protocol indications for smaller-volume taps.

2. Spontaneous Bacterial Peritonitis (SBP)

SBP is an acute bacterial infection of ascitic fluid occurring in the absence of an identifiable surgically treatable intra-abdominal source. It arises from bacterial translocation of enteric organisms (predominantly Escherichia coli , Klebsiella pneumoniae , and Streptococcus pneumoniae ) across an oedematous gut wall into mesenteric lymph nodes and ascitic fluid.

Diagnostic Criteria

Mandatory bedside paracentesis prior to antibiotic administration.

Diagnostic Threshold: Ascitic fluid polymorphonuclear (PMN) neutrophil count ≥ 250 cells/ μ L \ge 250\text{ cells/}\mu\text{L} ≥ 250 cells/ μ L ( 0.25 × 10 9 /L 0.25 \times 10^9\text{/L} 0.25 × 1 0 9 /L ).

Fluid should be directly inoculated into blood culture bottles at the bedside to maximize microbiological yield.

Therapeutic Management

Empirical Antibiotic Therapy: Initiate promptly upon finding PMN ≥ 250 / μ L \ge 250/\mu\text{L} ≥ 250/ μ L :

Intravenous Ceftriaxone 1 to 2 g daily (or intravenous cefotaxime 2 g 8-hourly) for 5 days .

Intravenous Human Albumin Infusion: Mandatory adjunctive therapy to prevent hepatorenal syndrome and reduce mortality:

  • 1.5 g/kg body weight within 6 hours of diagnosis
  • 1.0 g/kg body weight on Day 3

Albumin therapy reduces the incidence of hepatorenal syndrome from 30 % 30\% 30% to 10 % 10\% 10% and cuts hospital mortality from 29 % 29\% 29% to 10 % 10\% 10% .

Secondary Prophylaxis: Following recovery from a single episode of SBP, the 1-year recurrence rate reaches 70 % 70\% 70% . Indefinite oral antibiotic prophylaxis is mandatory (e.g. norfloxacin 400 mg daily or ciprofloxacin 500 mg daily) until liver transplantation or complete resolution of ascites.

3. Hepatic Encephalopathy (HE)

Hepatic encephalopathy is a reversible neuropsychiatric disturbance caused by gut-derived neurotoxins (predominantly ammonia ) bypassing hepatic metabolic clearance via intrahepatic shunting or portosystemic collaterals.

West Haven Staging

Grade 1: Subtle attention, personality or sleep changes; clear asterixis is more typical of grade 2. Exclude infection, medicines, glucose/electrolyte disturbance and intracranial disease.

Grade 2: Lethargy, marked apathy, slurred speech, obvious asterixis ('flapping tremor'), inappropriate behaviour.

Grade 3: Somnolence, stupor, gross disorientation, incoherent speech, but responsive to voice.

Grade 4: Comatose state, unresponsive to verbal stimuli; decerebrate or decorticate posturing.

Common Precipitating Factors (Must Be Actively Screened)

Infections: SBP, urinary tract infection, pneumonia.

Gastrointestinal Haemorrhage: Digestion of blood proteins delivers a massive ammonia load to the portal circulation.

Constipation: Prolonged colonic transit enhances enteric ammonia generation and mucosal absorption.

Electrolyte Derangements: Hypokalaemia and metabolic alkalosis (frequently caused by over-diuresis) promote the conversion of charged ammonium ( N H 4 + NH_4^+ N H 4 + ​ ) to uncharged, lipophilic ammonia ( N H 3 NH_3 N H 3 ​ ), which readily crosses the blood-brain barrier.

Dehydration / Prerenal Azotaemia: Reduces renal clearance of urea.

Sedating Medications: Benzodiazepines, opioids, z-drugs.

Management Algorithm

Identify and Correct the Underlying Trigger: Treat infection, stop diuretics, correct hypokalaemia, and control GI bleeding.

Lactulose (First-Line Therapy): Synthetic non-absorbable disaccharide fermented by colonic bacteria into lactic and acetic acid:

Luminal acidification ( p H < 5.0 pH < 5.0 p H < 5.0 ) protonates ammonia ( N H 3 NH_3 N H 3 ​ ) into non-absorbable ammonium ( N H 4 + NH_4^+ N H 4 + ​ ), trapping it for faecal evacuation ( ammonia trapping ).

Induces an osmotic cathartic effect.

Dosing: 20 − 30 mL 20-30\text{ mL} 20 − 30 mL orally two to four times daily, titrated to achieve 2 to 3 soft bowel motions per day .

Rifaximin (Second-Line / Add-on): Non-absorbable oral rifamycin antibiotic ( 550 mg twice daily ). Eradicates ammonia-producing gut bacteria. Indicated as adjunctive maintenance therapy following a second episode of hepatic encephalopathy to prevent recurrences.

Hepatorenal syndrome and AKI

In cirrhosis with ascites and AKI, assess infection, bleeding, nephrotoxins, volume status, urine findings and obstruction. ADQI–ICA 2024 no longer requires an automatic 48-hour albumin challenge. When clinically indicated volume resuscitation has failed to improve renal function within 24 hours and no stronger alternative explanation exists, assess HRS-AKI with hepatology. Give vasoconstrictor/albumin therapy with careful fluid and respiratory monitoring and consider transplantation. Treat triggers concurrently; albumin in an already overloaded patient can cause harm.

Hepatocellular Carcinoma (HCC) Surveillance

HCC accounts for > 90 % > 90\% > 90% of primary liver cancers in Australia, arising predominantly on a background of established cirrhosis.

High-Risk Target Populations

All patients with established cirrhosis (Child-Pugh Class A or B; transplant-eligible Class C) regardless of aetiology.

Non-cirrhotic chronic Hepatitis B carriers with high-risk features:

  • Asian males > 40 years > 40\text{ years} > 40 years ; Asian females > 50 years > 50\text{ years} > 50 years
  • African ethnicity > 20 years > 20\text{ years} > 20 years
  • Family history of hepatocellular carcinoma
  • High persistent HBV DNA viral load ( > 2000 IU/mL > 2000\text{ IU/mL} > 2000 IU/mL ) with active inflammation
  • Surveillance Protocol

Modality: Transabdominal Liver Ultrasonography every 6 months ± \pm ± serum alpha-fetoprotein (AFP) .

Six-month intervals reflect tumor doubling time, enabling detection of small, asymptomatic nodules ( < 2 − 3 cm < 2-3\text{ cm} < 2 − 3 cm ) amenable to curative therapies:

Surgical resection (single lesion in well-preserved Child-Pugh A liver without portal hypertension)

Orthotopic liver transplantation (meeting Milan Criteria: single lesion ≤ 5 cm \le 5\text{ cm} ≤ 5 cm or up to 3 lesions each ≤ 3 cm \le 3\text{ cm} ≤ 3 cm without macrovascular invasion or extrahepatic spread)

  • Radiofrequency ablation (RFA) or microwave ablation
  • Viral Hepatitis Serology Interpretation

Accurate interpretation of viral hepatitis panels is a high-yield AMC examination skill.

Hepatitis B Serology Matrix

Acute Hepatitis B : HBsAg: Positive ; Anti-HBs: Negative; Total Anti-HBc: Positive ; IgM Anti-HBc: Positive ; HBeAg: Positive; Anti-HBe: Negative

Chronic Hepatitis B (High replication) : HBsAg: Positive ( > 6 mo > 6\text{ mo} > 6 mo ); Anti-HBs: Negative; Total Anti-HBc: Positive ; IgM Anti-HBc: Negative; HBeAg: Positive ; Anti-HBe: Negative

Chronic Hepatitis B (Low replication) : HBsAg: Positive ( > 6 mo > 6\text{ mo} > 6 mo ); Anti-HBs: Negative; Total Anti-HBc: Positive ; IgM Anti-HBc: Negative; HBeAg: Negative; Anti-HBe: Positive

Natural Immunity (Resolved infection) : HBsAg: Negative; Anti-HBs: Positive ; Total Anti-HBc: Positive ; IgM Anti-HBc: Negative; HBeAg: Negative; Anti-HBe: Positive/Neg

Vaccine-Induced Immunity : HBsAg: Negative; Anti-HBs: Positive ; Total Anti-HBc: Negative ; IgM Anti-HBc: Negative; HBeAg: Negative; Anti-HBe: Negative

Window Period : HBsAg: Negative; Anti-HBs: Negative; Total Anti-HBc: Positive ; IgM Anti-HBc: Positive ; HBeAg: Variable; Anti-HBe: Variable

HBsAg (Surface Antigen): Hallmark of active infection (acute or chronic).

Anti-HBs (Surface Antibody): Marker of immunity and viral clearance. Protective titer is ≥ 10 mIU/mL \ge 10\text{ mIU/mL} ≥ 10 mIU/mL .

Anti-HBc Total (Core Antibody): Marker of natural viral exposure; positive in anyone who has ever contracted HBV. Crucially negative in individuals with vaccine-induced immunity .

IgM Anti-HBc: Indicates acute infection (present during the initial 6 months) or an acute severe flare of chronic hepatitis B.

Hepatitis B: Interpret HBsAg, anti-HBc, anti-HBs and HBV DNA together. HBeAg negativity does not guarantee inactive infection: precore/core-promoter variants may replicate actively. Treatment and monitoring depend on DNA, ALT, fibrosis and clinical context.

HBV DNA PCR: Quantifies viral load; guides initiation of nucleoside/nucleotide reverse transcriptase inhibitors (entecavir, tenofovir disoproxil, or tenofovir alafenamide).

Hepatitis C Diagnosis & Direct-Acting Antivirals (DAAs)

Screening Test: Anti-HCV Antibody . Indicates exposure to HCV at any time in the past.

Confirmatory Test: HCV RNA PCR . Detects active, viraemic infection.

Anti-HCV Positive + HCV RNA Positive: Confirms active hepatitis C infection . Treat with oral DAAs.

Anti-HCV Positive + HCV RNA Negative: Indicates past resolved infection (spontaneous clearance occurs in 15 − 25 % 15-25\% 15 − 25% ) or successfully treated prior infection.

Treatment: Pan-genotypic direct-acting antivirals (e.g. sofosbuvir/velpatasvir for 12 weeks, or glecaprevir/pibrentasvir for 8 weeks) achieve Sustained Virological Response (SVR12) with cure rates > 95 % > 95\% > 95% .

Critical Rule for Cirrhotics: Patients with cirrhosis who achieve SVR remain at persistent, lifelong risk of developing hepatocellular carcinoma and must continue 6-monthly ultrasound surveillance indefinitely .

Primary references (checked 7 October 2026): ADQI–ICA cirrhosis/AKI consensus .